Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-625,900
Closed -$61.6M 463
2025
Q2
$61.6M Buy
625,900
+216,100
+53% +$20.4M 1.46% 8
2025
Q1
$38M Sell
409,800
-231,800
-36% -$21.4M 1.16% 15
2024
Q4
$58.3M Buy
641,600
+629,100
+5,033% +$57.8M 1.41% 16
2024
Q3
$1.21M Sell
12,500
-2,200
-15% -$215K 0.02% 456
2024
Q2
$1.35M Buy
+14,700
New +$1.36M 0.03% 465
2024
Q1
Sell
-9,400
Closed -$894K 366
2023
Q4
$894K Buy
+9,400
New +$878K 0.02% 507

Other funds holding AMED

Maven Securities's AMED Position: Q2 2025 in Review

Maven Securities sold out of Amedisys (AMED) in Q2 2025, closing a stake of 5,000 shares — an estimated $473K sold.

Maven Securities first reported a position in AMED in Q2 2024 and held it in 4 quarters. The position peaked at $3.32M in Q4 2024. 319 funds tracked by Wall St. Rank hold AMED as of Q2 2025.

  • Maven Securities reported no remaining Amedisys position as of Q2 2025 after selling out during the quarter.
  • Maven Securities sold 5,000 Amedisys shares in Q2 2025, an estimated $473K.
  • Maven Securities first reported a position in Amedisys in Q2 2024 and held it in 4 quarters.
  • Maven Securities's Amedisys position peaked at $3.32M in Q4 2024.
  • 319 funds tracked by Wall St. Rank held Amedisys as of Q2 2025.

Based on Maven Securities's 13F filing for Q2 2025, filed 14 Aug 2025.